Enlivex Progresses to Phase II for Knee Arthritis Treatment
Company Announcements

Enlivex Progresses to Phase II for Knee Arthritis Treatment

Enlivex (ENLV) has released an update.

Enlivex Therapeutics Ltd. has announced the successful completion of Phase I trials for Allocetra, a treatment for knee osteoarthritis, with the DSMB endorsing the move to Phase II. This next stage will be a double-blind, randomized trial to assess the safety and efficacy of the treatment compared to a placebo. The therapy is a significant development, considering the large number of individuals affected by osteoarthritis globally, with no current FDA or EMA-approved medications that can halt or reverse joint damage.

For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskEnlivex Initiates Promising Trial for Psoriatic Arthritis
TheFlyEnlivex completes dosing, follow-up for first patient in study of Allocetra
TipRanks Auto-Generated NewsdeskEnlivex Advances Allocetra Trial for Knee Osteoarthritis
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App